- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07314164
Étude du cabozantinib chez les participants atteints de tumeurs neuroendocrines ayant déjà reçu un traitement antérieur (CaboLife)
CaboLife : Étude prospective non interventionnelle sur l'efficacité et la sécurité du cabozantinib en situation réelle pour les patients prétraités atteints de tumeur neuroendocrine
This study will assess how well cabozantinib works and how safe it is in adults with a type of cancer called neuroendocrine tumors (NETs).
These tumors can appear in all parts of the body. All participants in this study have already received at least one treatment that affects the whole body to help manage their cancer, but their disease has continued to grow.
The study will take place in regular hospitals and clinics in Germany and Austria.
It will follow about 150 participants who are taking cabozantinib as part of their usual care. Doctors will collect information from routine medical visits, tests, and scans to see how the cancer responds to treatment and how long participants stay on cabozantinib. They will also look at side effects and how the treatment affects participants' quality of life.
This is an observational study, which means that no extra tests or procedures will be done beyond what is normally used to care for participants with this condition.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Ipsen Clinical Study Enquiries
- Numéro de téléphone: See e mail
- E-mail: clinical.trials@ipsen.com
Lieux d'étude
-
-
-
Aschaffenburg, Allemagne
- Recrutement
- MVZ am Klinikum Aschaffenburg
-
Berlin, Allemagne
- Recrutement
- Evangelische Lungenklinik Berlin
-
Berlin, Allemagne
- Recrutement
- DRK Kliniken Berlin
-
Berlin, Allemagne
- Recrutement
- Charité - Universitaetsmedizin Berlin
-
Bonn, Allemagne
- Pas encore de recrutement
- Johanniter-Kliniken Bonn
-
Bremen, Allemagne
- Recrutement
- Krankenhaus St. Joseph-Stift Bremen GmbH
-
Chemnitz, Allemagne
- Pas encore de recrutement
- Klinikum Chemnitz
-
Cologne, Allemagne
- Recrutement
- pioh Studien und Mangement GbR
-
Cologne, Allemagne
- Recrutement
- MVZ fuer Haematologie und Onkologie Koeln am Sachsenring
-
Dresden, Allemagne
- Recrutement
- Gemeinschaftspraxis Haematologie - Onkologie
-
Dresden, Allemagne
- Recrutement
- Technische Univiersitaet (TU) Dresden
-
Erlangen, Allemagne
- Recrutement
- Universitaetsklinikum Erlangen
-
Essen, Allemagne
- Recrutement
- Universitaetsklinikum Essen
-
Frankfurt, Allemagne
- Pas encore de recrutement
- Krankenhaus Nordwest
-
Frankfurt am Main, Allemagne
- Pas encore de recrutement
- Uniklinikum Frankfurt
-
Freiburg im Breisgau, Allemagne
- Recrutement
- Universitaetsklinikum Freiburg
-
Giesen, Allemagne
- Pas encore de recrutement
- Universitaetsklinikum Giessen-Marburg
-
Goettigen, Allemagne
- Recrutement
- Universitaetsmedizin Goettingen
-
Hamburg, Allemagne
- Recrutement
- Universitaetsklinikum Hamburg-Eppendorf
-
Hamburg, Allemagne
- Pas encore de recrutement
- Asklepios Kliniken Hamburg
-
Heidelberg, Allemagne
- Pas encore de recrutement
- Universitaetsklinikum Heidelberg
-
Kiel, Allemagne
- Pas encore de recrutement
- UKSH Kiel
-
Leer, Allemagne
- Pas encore de recrutement
- Studienzentrum UnterEms
-
Leipzig, Allemagne
- Pas encore de recrutement
- MVZ Leipzig Mitte, MVZ Delitzsch
-
Leipzig, Allemagne
- Pas encore de recrutement
- Universiteatsmedizin Leipzig
-
Ludwigsburg, Allemagne
- Recrutement
- RKH Kliniken Ludwigsburg-Bietigheim gGmbH
-
Lübeck, Allemagne
- Pas encore de recrutement
- UKSH Luebeck
-
Mainz, Allemagne
- Pas encore de recrutement
- Universitaetsmedizin Mainz
-
Marburg, Allemagne
- Recrutement
- Philipps-Universitaet Marburg
-
Minden, Allemagne
- Recrutement
- Johannes Wesling Klinikum Minden der Muehlenkreiskliniken AoeR
-
Mülheim, Allemagne
- Recrutement
- MVZ Muelheim an der Ruhr GmbH
-
München, Allemagne
- Pas encore de recrutement
- TUM Klinikum Muenchen
-
Münster, Allemagne
- Pas encore de recrutement
- Universitaetsklinikum Muenster
-
Osnabrück, Allemagne
- Pas encore de recrutement
- MVZ Onkologie Klinikum Osnabrueck GmbH
-
Saarbrücken, Allemagne
- Pas encore de recrutement
- Universitaestklinikum Saarbruecken
-
Tübingen, Allemagne
- Recrutement
- Universitätsklinikum Tuebingen
-
Westerstede, Allemagne
- Recrutement
- Medizinische Studiengesellschaft Nord-West
-
Würzburg, Allemagne
- Recrutement
- Universitaetsklinikum Wuerzburg
-
-
-
-
-
Graz, L'Autriche
- Recrutement
- Medizinische Universitaet Graz
-
Linz, L'Autriche
- Pas encore de recrutement
- Kepler Universitaetsklinikum GmbH Linz
-
Vienna, L'Autriche
- Recrutement
- Medizinische Universität Wien
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
150 adult participants in Austria and Germany who are prescribed cabozantinib tablets for unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumours who have progressed following at least one prior systemic therapy other than somatostatin analogues prior to entry into the study will be included.
La description
Inclusion Criteria:
Participants can join the study if they meet all of the following conditions:
- Are 18 years or older and able to give informed consent.
- Have a physician-initiated decision to start treatment with cabozantinib for neuroendocrine tumors (NETs), made before joining the study.
- Have unresectable or metastatic, well-differentiated pancreatic (pNET) or extra-pancreatic neuroendocrine tumors (epNET).
- Have already received at least one prior systemic therapy, other than somatostatin analogues.
- Have signed a written informed consent form.
Exclusion Criteria:
Participants cannot join the study if:
- They are currently participating in an interventional clinical trial, or have done so within the last 3 months before joining this study.
- They have a contraindication to cabozantinib treatment, based on the product's official prescribing information.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Disease Control Rate (DCR)
Délai: At 6 Months
|
Proportion of participants who achieve complete response, partial response, or stable disease within 6 months of cabozantinib treatment, based on radiographic assessments performed as part of routine care. |
At 6 Months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Objective Response Rate (ORR)
Délai: Up to 18 Months
|
Proportion of participants who achieve complete or partial response based on radiographic assessments. |
Up to 18 Months
|
|
Change from baseline in global and subscale scores of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30)
Délai: Baseline and Every 3 Months up to 18 Months
|
A validated 30-item questionnaire designed to assess the general health-related quality of life of cancer patients. It includes: 5 functional scales (physical, role, emotional, cognitive, social), 3 symptom scales (fatigue, nausea/vomiting, pain) a global health status/QoL scale and several single items (e.g., dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). |
Baseline and Every 3 Months up to 18 Months
|
|
Change from baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Gastrointestinal Neuroendocrine Tumors Module (EORTC QLQ-GINET21)
Délai: Baseline and Every 3 Months up to 18 Months
|
A 21-item module developed to supplement the QLQ-C30 for patients with gastrointestinal neuroendocrine tumors (GI-NETs). It includes 5 scales (Endocrine symptoms, Gastrointestinal symptoms, Treatment-related side effects, Social functioning, Disease-related worries) and 5 single items (weight loss, weight gain, muscle and/or bone pain, information, sexual functioning). |
Baseline and Every 3 Months up to 18 Months
|
|
Percentage of participants experiencing Adverse Events (AEs), non-serious, drug-related, or serious Adverse Events (SAEs)
Délai: Up to 18 Months
|
An Adverse event (AE) is any untoward medical occurrence, temporally associated with the use of study intervention, whether or not related to the study intervention. |
Up to 18 Months
|
|
Percentage of participants with any dose modification due to AEs.
Délai: Up to 18 months
|
Percentage of participants who experienced at least one dose reduction, interruption, or discontinuation due to adverse events during the study period. |
Up to 18 months
|
|
Duration of treatment (DoT)
Délai: Up to 18 Months
|
Time from first dose to last dose of cabozantinib. |
Up to 18 Months
|
|
Percentage of participants switching to a new line of therapy
Délai: Up to 18 Months
|
Percentage of participants who initiated a new line of therapy during the study period. The type of therapy received after switch will be reported descriptively and is not considered a formal outcome measure. |
Up to 18 Months
|
|
Disease control rate after switch to next line of therapy
Délai: 3 Months After Therapy Switch
|
Proportion of participants achieving complete response, partial response, or stable disease within 3 months after switching to a new therapy, based on radiographic assessment performed as part of routine care. |
3 Months After Therapy Switch
|
|
Chromogranin A Levels
Délai: Baseline and Every 3 Months up to 18 Months
|
Chromogranin A blood levels measured during routine care. |
Baseline and Every 3 Months up to 18 Months
|
|
Neuron-Specific Enolase blood levels.
Délai: Baseline and Every 3 Months up to 18 Months
|
Neuron-Specific Enolase blood levels measured during routine care. |
Baseline and Every 3 Months up to 18 Months
|
|
Time to next treatment
Délai: Up to 18 Months
|
Time from first dose of cabozantinib to initiation of subsequent therapy. |
Up to 18 Months
|
|
Progression-Free Survival (PFS)
Délai: Up to 18 Months
|
Time from first dose of cabozantinib to disease progression or death from any cause. |
Up to 18 Months
|
|
Progression-Free Survival Rate at 12 and 18 Months
Délai: At 12 and 18 Months
|
Number of participants without disease progression or death. |
At 12 and 18 Months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Ipsen Medical Director, Ipsen
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CLIN-60000-467
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.
Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
Délai de partage IPD
Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the United States (US) and/or Europe (EU).
Critères d'accès au partage IPD
Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .